Neal D. Shore, MD, presented “Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer” for the Grand Rounds in Urology audience in November 2019.

How to cite: Shore, Neal D. “Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer” November, 2019. Accessed Dec 2019. https://grandroundsinurology.com/phase-iii-hero-trial/

Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer – Summary:

Neal D. Shore, MD, a HERO Program Steering Committee Member, discusses the results of his group’s global, prospective, randomized, phase III trial. This trial evaluated once-daily, oral relugolix, a gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of advanced prostate cancer against a control arm of patients receiving 3-month leuprolide injections. The primary endpoint of sustained testosterone suppression for 48 weeks was met, as well as 6 key secondary endpoints, and the reported major adverse cardiovascular events favored relugolix over the control arm.